Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeanine M Walenga

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Pathophysiology of Haemostasis and Thrombosis|June 18, 2003
An overview of the direct thrombin inhibitor argatrobanJeanine M Walenga
Journal De Medecine Vasculaire|May 14, 2020
Heparin: Much more than anti-IIa/anti-XaJeanine M Walenga
Clinical Advances in Hematology & Oncology : H&O|November 14, 2007
Non-anticoagulant effects of unfractionated and low-molecular weight heparinsJeanine M Walenga
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 27, 2022
Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?Jeanine M Walenga
Seminars in Thrombosis and Hemostasis|April 9, 2008
The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an updateMargaret Prechel, Jeanine M Walenga
Thrombosis Journal|June 21, 2007
Why differentiate low molecular weight heparins for venous thromboembolism?Jawed Fareed, Jeanine M Walenga
Seminars in Thrombosis and Hemostasis|March 9, 2012
Heparin-induced thrombocytopenia: an updateMargaret Prechel, Jeanine M Walenga
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 2, 2009
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulantsGilles Montalescot, Jeanine M Walenga
Methods in Molecular Medicine|January 22, 2004
Antithrombotic drugs for the treatment of heparin-induced thrombocytopeniaWalter P Jeske, Jeanine M Walenga
Thrombosis Journal|April 9, 2013
Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced ThrombocytopeniaM Margaret Prechel, Jeanine M Walenga
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Pathophysiology of Haemostasis and Thrombosis|June 18, 2003
An overview of the direct thrombin inhibitor argatrobanJeanine M Walenga
Journal De Medecine Vasculaire|May 14, 2020
Heparin: Much more than anti-IIa/anti-XaJeanine M Walenga
Clinical Advances in Hematology & Oncology : H&O|November 14, 2007
Non-anticoagulant effects of unfractionated and low-molecular weight heparinsJeanine M Walenga
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 27, 2022
Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?Jeanine M Walenga
Seminars in Thrombosis and Hemostasis|April 9, 2008
The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an updateMargaret Prechel, Jeanine M Walenga
Thrombosis Journal|June 21, 2007
Why differentiate low molecular weight heparins for venous thromboembolism?Jawed Fareed, Jeanine M Walenga
Seminars in Thrombosis and Hemostasis|March 9, 2012
Heparin-induced thrombocytopenia: an updateMargaret Prechel, Jeanine M Walenga
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 2, 2009
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulantsGilles Montalescot, Jeanine M Walenga
Methods in Molecular Medicine|January 22, 2004
Antithrombotic drugs for the treatment of heparin-induced thrombocytopeniaWalter P Jeske, Jeanine M Walenga
Thrombosis Journal|April 9, 2013
Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced ThrombocytopeniaM Margaret Prechel, Jeanine M Walenga
Pageof 10